Elutia Inc. (ELUT)
3.00
-0.01 (-0.33%)
At close: Jan 29, 2025, 3:59 PM
2.99
-0.33%
After-hours Jan 29, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.3 |
| Market Cap | 103.69M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.35 |
| PE Ratio (ttm) | -1.28 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.78 |
| Volume | 14,174 |
| Avg. Volume (20D) | 38,106 |
| Open | 3.00 |
| Previous Close | 3.01 |
| Day's Range | 2.94 - 3.17 |
| 52-Week Range | 2.28 - 5.24 |
| Beta | undefined |
About ELUT
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2020
Employees 54
Stock Exchange NASDAQ
Ticker Symbol ELUT
Website https://elutia.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ELUT stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 233.33% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Elutia Inc. is scheduled to release its earnings on Mar 6, 2025,
during market hours.
Analysts project revenue of $6.40M, reflecting a 8.94% YoY growth and earnings per share of -0.25, making a -62.12% decrease YoY.
Analysts project revenue of $6.40M, reflecting a 8.94% YoY growth and earnings per share of -0.25, making a -62.12% decrease YoY.
7 months ago
-16.97%
Elutia shares are trading lower after the company ...
Unlock content with
Pro Subscription
